Clinical Trials Logo

Medullary Thyroid Cancer clinical trials

View clinical trials related to Medullary Thyroid Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04161391 Terminated - Clinical trials for Non Small Cell Lung Cancer

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Start date: December 6, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET mutations or alterations. The study consists of three portions: 1) Phase 1 Dose Escalation and Food Effect Sub-study, and 2) Phase 1 dose expansion and 3) Phase 2 efficacy evaluation.

NCT ID: NCT02709889 Terminated - Glioblastoma Clinical Trials

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Start date: September 23, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.

NCT ID: NCT02363647 Terminated - Colon Cancer Clinical Trials

Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer

Start date: January 2015
Phase: N/A
Study type: Interventional

The Personalized Discovery Process is the only program offering patients treatment recommendations based on an empirically constructed Drosophila "fly" model of their disease. Special committee selects one of the one of the few 2-3 FDA approved drug combinations or single agents that improved survival in the fly cancer model.

NCT ID: NCT00582712 Terminated - Clinical trials for Medullary Thyroid Cancer

An Initial Study of Lithium in Patients With Medullary Thyroid Cancer

Start date: January 2008
Phase: Phase 2
Study type: Interventional

Primary objective is to evaluate the tumor response rate of patients with MTC treated with Lithium carbonate